The ability of both ligands to simultaneously engage the MUC1 tandem-repeat domain without inducing unfavorable steric or energetic penalties supports the rational design of multi-ligand nanocarrier systems for improved delivery and specificity in MUC1-overexpressing cancers. This evidence concerns the gene MUC1 and cancer.